Abstract
ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumor suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory reports on its relationship to outcome, immune response, and correlation with clinicopathological features. We assembled a series of 1623 endometriosis-associated ovarian carcinomas, including 1078 endometrioid (ENOC) and 545 clear cell (CCOC) ovarian carcinomas through combining resources of the Ovarian Tumor Tissue Analysis (OTTA) Consortium, the Canadian Ovarian Unified Experimental Resource (COEUR), local, and collaborative networks. Validated immunohistochemical surrogate assays for ARID1A mutations were applied to all samples. We investigated associations between ARID1A loss/mutation, clinical features, outcome, CD8+ tumor-infiltrating lymphocytes (CD8+ TIL), and DNA mismatch repair deficiency (MMRd). ARID1A loss was observed in 42% of CCOC and 25% of ENOC. We found no associations between ARID1A loss and outcomes, stage, age, or CD8+ TIL status in CCOC. Similarly, we found no association with outcome or stage in endometrioid cases. In ENOC, ARID1A loss was more prevalent in younger patients (p=0.012), and associated with MMRd (p<0.001), and presence of CD8+ TIL (p=0.008). Consistent with MMRd being causative of ARID1A mutations, in a subset of ENOC we also observed an association between ARID1A loss-of-function mutation as a result of small indels (p=0.011, vs. single nucleotide variants). In ENOC, the association between ARID1A loss, CD8+ TIL, and age, appears confounded by MMRd status. Although this observation does not explicitly rule out a role for ARID1A influence on CD8+ TIL infiltration in ENOC, given current knowledge regarding MMRd, it seems more likely that effects are dominated by the hypermutation phenotype. This large dataset with consistently applied biomarker assessment now provides a benchmark for the prevalence of ARID1A loss-of-function mutations in endometriosis-associated ovarian cancers and brings clarity to the prognostic significance.
Competing Interest Statement
AdB received honoraria for advisory boards and/or lecturing from Roche, GSK/Tesaro, Astra Zeneca, BIOCAD, Clovis, Zodiac, Seagen, Pfizer. PH received grants and personal fees from Astra Zeneca, Roche, Clovis, Immunogen, GSK; grant support by Boehringer Ingelheim, Medac, Genmab, and public funding agencies (EU, DFG, German Cancer Aid) as well as personal fees from Sotio, Stryker, Zai Lab, MSD. MJS is employed by IQVIA since February 2021. DGH is a co-founder and shareholder of Contextual Genomics Inc., a somatic mutation testing laboratory; the company’s work and interests do not overlap with the subject of and methodologies used in this article. DGH is an Associate Editor of The Journal of Pathology. The other authors declare no conflict of interest.
Funding Statement
This research was funded in part by the Janet D. Cottrelle Foundation and the Canadian Institutes of Health Research (Early Career Investigator Grant to M.S. Anglesio). K. Heinze is funded through a research scholarship by the Deutsche Forschungsgesellschaft (HE 8699/1-1). A. Talhouk is funded through a Michael Smith Foundation for Health Research Scholar Award. M. Koebel received support through the Calgary Laboratory Services research support fund (RS19-612). M.S. Anglesio is funded through a Michael Smith Foundation for Health Research Scholar Award and the Janet D. Cottrelle Foundation Scholars program managed by the BC Cancer Foundation. BC’s Gynecological Cancer Research team (OVCARE) receives support through the BC Cancer Foundation and The VGH+UBC Hospital Foundation. This study uses resources provided by the Canadian Ovarian Cancer Research Consortium’s COEUR biobank funded by the Terry Fox Research Institute and managed and supervised by the Centre hospitalier de l’Universite de Montreal (CRCHUM). The Consortium acknowledges contributions to its COEUR biobank from Institutions across Canada (for a full list see http://www.tfri.ca/en/research/translational-research/coeur/coeur_biobanks.aspx).
Ovarian tumor tissue analysis consortium studies were supported through independent mechanisms. The WMH study was supported by the Westmead Hospital Department of Gynaecological Oncology. The Gynaecological Oncology Biobank at Westmead, a member of the Australasian Biospecimen Network-Oncology group, was funded by the National Health and Medical Research Council Enabling Grants ID 310670 & ID 628903 and the Cancer Institute NSW Grants ID 12/RIG/1-17 & 15/RIG/1-16. The Westmead GynBiobank acknowledges financial support from the Sydney West Translational Cancer Research Centre. The Sydney West Translational Cancer Research Centre is funded by the Cancer Institute NSW. The BGS is funded by Breast Cancer Now and the Institute of Cancer Research (ICR). ICR acknowledges NHS funding to the NIHR Biomedical Research Centre. The SWE study, KS, CM, AL and the GynCancer Biobank in Western Sweden is financed by Swedish Cancer foundation (KS), Swedish state under the agreement between the Swedish government and the county council, the ALF-agreement (KS) and Assar Gabrielsson foundation (CM, AL). The DOV study is funded by National Health Institute grants ID R01-CA168758, R01-CA112523 and R01-CA087538. The GER study was supported by the German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research (01 GB 9401) and the German Cancer Research Center (DKFZ), and thanks Sabine Behrens for competent technical assistance. The HAW study was funded by National Institute of Health and National Cancer Institute Grants ID N01-CN-25403/CN, N01-CN-67001/CN, P30-CA-71789/CA and R01-CA-58598/CA. The HOP study was supported by National Institute of Health and National Cancer Institute Grants ID K07-CA80668, R01CA095023, and R01 CA126841, as well as by US Army Medical Research and Materiel Command DAMD17-02-1-0669 and NIH/National Center for Research Resources/General Clinical Research Center grant MO1- RR000056. MW is funded by the European Research Council Advanced Grant (H2020 BRCA-ERC under Grant Agreement No. 742432).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Detailed information in ‘Table_S1-Study-Cohort.xlsx’
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is contained within the manuscript and or associated supplemental information.
Abbreviations
- CCOC
- clear cell ovarian carcinoma
- COEUR
- Canadian Ovarian Unified Experimental Resource
- EAOC
- endometriosis-associated ovarian carcinoma
- ENOC
- endometrioid ovarian carcinoma
- HGSOC
- high grade serous ovarian carcinoma
- IHC
- immunohistochemistry
- LOF
- loss-of-function (expression)
- MMRd
- mismatch repair deficient
- MSI
- microsatellite instability
- OS
- overall survival
- OTTA
- ovarian tumor tissue analysis consortium
- PFS
- progression-free survival
- TIL
- tumor infiltrating lymphocytes
- TMA
- tissue microarray
